PMID- 20374384
OWN - NLM
STAT- MEDLINE
DCOM- 20100706
LR  - 20131121
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 13
IP  - 1
DP  - 2010 Feb 1
TI  - The effects of an orally administered probiotic on sulfasalazine metabolism in 
      individuals with rheumatoid arthritis: a preliminary study.
PG  - 48-54
LID - 10.1111/j.1756-185X.2009.01449.x [doi]
AB  - AIM: To carry out a pilot study to investigate the effect of short-term oral 
      probiotic administration on the metabolism of sulfasalazine (SSZ) in patients 
      with rheumatoid arthritis (RA) stabilized on SSZ. METHODS: Twelve subjects with 
      RA taking stable doses of SSZ for a minimum of 3 months prior to the study, 
      received a probiotic preparation contained three strains of bacteria (1.8 x 10(9) 
      CFU/day) twice daily for 1 week. Single point blood and 12-h urine samples were 
      taken before and after probiotic treatment and 3 weeks following discontinuation 
      of probiotics, for determination of SSZ and its metabolites. The presence of the 
      probiotic bacteria in the feces of patients was investigated by denaturing 
      gradient gel electrophoresis (DGGE). RESULTS: Adverse events recorded were three 
      instances of gastrointestinal disturbance and one flare of RA. Plasma and urinary 
      levels of SSZ and its metabolites showed no statistically significant changes 
      after probiotic administration and the incidence of gastrointestinal disturbance 
      did not appear to be ascribed to higher sulfapyridine plasma levels. 
      Probiotic-specific DGGE bands were detected in the feces of some patients after 
      the treatment period. CONCLUSIONS: Short-term treatment of RA patients with a 
      multi-strain probiotic did not significantly influence SSZ metabolism as has been 
      demonstrated in animal models.
FAU - Lee, Hee Ji
AU  - Lee HJ
AD  - School of Pharmacy, University of Otago, Dunedin, New Zealand. 
      leehe826@student.otago.ac.nz
FAU - Waller, Rosmary D
AU  - Waller RD
FAU - Stebbings, Simon
AU  - Stebbings S
FAU - Highton, John
AU  - Highton J
FAU - Orlovich, David A
AU  - Orlovich DA
FAU - Schmierer, David
AU  - Schmierer D
FAU - Fawcett, J Paul
AU  - Fawcett JP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antirheumatic Agents)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - Y5V2N1KE8U (Sulfapyridine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/adverse effects/blood/*metabolism/*therapeutic use/urine
MH  - Arthritis, Rheumatoid/*drug therapy/microbiology
MH  - Bifidobacterium/growth & development/metabolism
MH  - Biotransformation
MH  - Drug Interactions
MH  - Feces/microbiology
MH  - Female
MH  - Humans
MH  - Lactobacillus acidophilus/growth & development/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Probiotics/*administration & dosage/adverse effects
MH  - Streptococcus/growth & development/metabolism
MH  - Sulfapyridine/blood/urine
MH  - Sulfasalazine/adverse effects/blood/*metabolism/*therapeutic use/urine
EDAT- 2010/04/09 06:00
MHDA- 2010/07/07 06:00
CRDT- 2010/04/09 06:00
PHST- 2010/04/09 06:00 [entrez]
PHST- 2010/04/09 06:00 [pubmed]
PHST- 2010/07/07 06:00 [medline]
AID - APL1449 [pii]
AID - 10.1111/j.1756-185X.2009.01449.x [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2010 Feb 1;13(1):48-54. doi: 10.1111/j.1756-185X.2009.01449.x.